Jun Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jun Liang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Dan Xu
The People’s Hospital Wuxi Huishan Region
3 shared publicationsYing Qian
The People’s Hospital Wuxi Huishan Region
3 shared publicationsHuijuan Pan
The People’s Hospital Wuxi Huishan Region
2 shared publicationsMin Li
The People’s Hospital Wuxi Huishan Region
2 shared publicationsHui-Juan Pan
1 shared publicationJianwu Xi
The People’s Hospital Wuxi Huishan Region
1 shared publication
Latest Publications
- 19 December 2013
- Published by Springer Nature in The Chinese-German Journal of Clinical Oncology
- Vol. 12 (12) , 564-567
Effect and mechanism of 125I radioactive particles interposed radiotherapy between organizations on lung cancer
- 19 December 2013
- Published by Springer Nature in The Chinese-German Journal of Clinical Oncology
- Vol. 12 (12) , 564-567
Effect and mechanism of 125I radioactive particles interposed radiotherapy between organizations on lung cancer
- 17 October 2013
- Published by Springer Nature in The Chinese-German Journal of Clinical Oncology
- Vol. 12 (10) , 498-501
Raltitrexed arterial infusion chemotherapy analysis
- 17 October 2013
- Published by Springer Nature in The Chinese-German Journal of Clinical Oncology
- Vol. 12 (10) , 498-501
Raltitrexed arterial infusion chemotherapy analysis
- Open Access
- 30 June 2013
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 14 (6) , 3851-3854
Serum Tumor Markers, Hypoxia-Inducible factor-1α HIF-1α and Vascular Endothelial Growth Factor, in Patients with Non-small Cell Lung Cancer Before and after Intervention
To explore changes in the serum tumor makers, hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) level and their relations in patients with non-small cell lung cancer (NSCLC) before and after intervention. Forty patients with NSCLC and 40 healthy individuals undergoing physical examination in our hospital provided the observation and control groups. HIF-1α and VEGF levels in serum were detected by enzyme-linked immuno-sorbent assay (ELISA) in the observation group before and after intervention and in control group on the day of physical examination, along with serum carcino-embryonic antigen (CEA), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) levels in the observation group with a fully automatic biochemical analyzer. Clinical effects and improvement of life quality in the observation group were also evaluated. The total effective rate and improvement of life quality after treatment in observation group were 30.0% and 32.5%, respectively. Serum HIF-1α and VEGF levels in the control group were lower than that in observation group (p<0.01), but remarkably elevated after intervention (p<0.01). In addition, serum CEA, NSE and SCC levels were apparently lowered by treatment (p<0.01). Serum HIF-1α demonstrated a positive relation with VEGF level (p<0.01) and was inversely related with CEA, NSE and SCC levels (p<0.01). Significant correlations exist between marked increase of serum HIF-1α and VEGF levels and decrease of indexes related to hematological tumor markers in NSCLC patients after intervention.
- 30 June 2013
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 14 (6) , 3851-3854
Open AccessSerum Tumor Markers, Hypoxia-Inducible factor-1α HIF-1α and Vascular Endothelial Growth Factor, in Patients with Non-small Cell Lung Cancer Before and after Intervention
To explore changes in the serum tumor makers, hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) level and their relations in patients with non-small cell lung cancer (NSCLC) before and after intervention. Forty patients with NSCLC and 40 healthy individuals undergoing physical examination in our hospital provided the observation and control groups. HIF-1α and VEGF levels in serum were detected by enzyme-linked immuno-sorbent assay (ELISA) in the observation group before and after intervention and in control group on the day of physical examination, along with serum carcino-embryonic antigen (CEA), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) levels in the observation group with a fully automatic biochemical analyzer. Clinical effects and improvement of life quality in the observation group were also evaluated. The total effective rate and improvement of life quality after treatment in observation group were 30.0% and 32.5%, respectively. Serum HIF-1α and VEGF levels in the control group were lower than that in observation group (p<0.01), but remarkably elevated after intervention (p<0.01). In addition, serum CEA, NSE and SCC levels were apparently lowered by treatment (p<0.01). Serum HIF-1α demonstrated a positive relation with VEGF level (p<0.01) and was inversely related with CEA, NSE and SCC levels (p<0.01). Significant correlations exist between marked increase of serum HIF-1α and VEGF levels and decrease of indexes related to hematological tumor markers in NSCLC patients after intervention.